Barbara Schaeffler

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

Messoud Ashina, Joel R. Saper, Roger Cady et al. · Cephalalgia · 2020 · 397 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Efficacy and safety of eptinezumab in patients with chronic migraine

Richard B. Lipton, Peter J. Goadsby, Jeff Smith et al. · Neurology · 2020 · 392 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

Stephen D. Silberstein, Merle L. Diamond, Nada Hindiyeh et al. · The Journal of Headache and Pain · 2020 · 103 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

David Kudrow, Roger Cady, Brent Allan et al. · BMC Neurology · 2021 · 96 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine

Brian Baker, Barbara Schaeffler, Martin Béliveau et al. · Pharmacology Research & Perspectives · 2020 · 68 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17